On Thursday, BeOne Medicines Ltd. (ONC.US) shares climbed more than 6% in premarket trading to $402.98.
Financial results showed that the company posted total operating revenue of RMB 34.993 billion for the first three quarters, up 26.8% year on year, while net profit attributable to shareholders reached RMB 6.055 billion, up 431.8% year on year.
On a quarterly basis, the company recorded total operating revenue of RMB 12.774 billion in the third quarter, up 26.8% year on year, with net profit attributable to shareholders of RMB 2.785 billion, up 304.3% year on year.
In the third quarter of 2026, product revenue reached RMB 12.560 billion, compared with RMB 9.954 billion in the same period last year. The growth in product revenue was mainly driven by increased sales of the company's self-developed products BRUKINSA® (zanubrutinib capsules) and TEVIMBRA® (tislelizumab injection), as well as Amgen-licensed products.
BeOne Medicines further raised its full-year guidance, stating that it expects 2026 operating revenue to be between RMB 46.3 billion and RMB 47.0 billion, up from its previous forecast of RMB 44.9 billion to RMB 46.2 billion.
Comments